Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nabilone in adults with OCD
NCT02911324Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Sep 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nabilone in obsessive compulsive disorder (OCD) (2 arms), sponsored by New York State Psychiatric Institute. Primary endpoint: Change in Yale-Brown Obsessive Compulsive Scale at 4 weeks. Started Sep 2016; status: completed.
02
Drugs
nabilone
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT02911324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02911324.